Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Thomas Luger; Mark Boguniewicz; Warner Carr; Michael Cork; Mette Deleuran; Lawrence Eichenfield; Philippe Eigenmann; Regina Fölster-Holst; Carlo Gelmetti; Harald Gollnick; Eckard Hamelmann; Adelaide A. Hebert; Antonella Muraro; Arnold P. Oranje; Amy S. Paller; Carle Paul; Luis Puig; Johannes Ring; Elaine Siegfried; Jonathan M. Spergel; Georg Stingl; Alain Taieb; Antonio Torrelo; Thomas Werfel; Ulrich Wahn

doi:10.1111/pai.12331

Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Thomas Luger, Mark Boguniewicz, Warner Carr, Michael Cork, Mette Deleuran, Lawrence Eichenfield, Philippe Eigenmann, Regina Fölster-Holst, Carlo Gelmetti, Harald Gollnick, Eckard Hamelmann, Adelaide A. Hebert, Antonella Muraro, Arnold P. Oranje, Amy S. Paller, Carle Paul, Luis Puig, Johannes Ring, Elaine Siegfried, Jonathan M. SpergelGeorg Stingl, Alain Taieb, Antonio Torrelo, Thomas Werfel, Ulrich Wahn

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (

Original language	English
Pages (from-to)	306-315
Number of pages	10
Journal	Pediatric Allergy and Immunology
Volume	26
Issue number	4
DOIs	https://doi.org/10.1111/pai.12331
Publication status	Published - Jun 1 2015

Keywords

Atopic dermatitis
Eczema
Infants
Paediatric
Pimecrolimus
Safety
Tacrolimus
Topical calcineurin inhibitors
Topical corticosteroids

ASJC Scopus subject areas

Immunology and Allergy
Pediatrics, Perinatology, and Child Health
Immunology

Access to Document

10.1111/pai.12331

Cite this

Luger, T., Boguniewicz, M., Carr, W., Cork, M., Deleuran, M., Eichenfield, L., Eigenmann, P., Fölster-Holst, R., Gelmetti, C., Gollnick, H., Hamelmann, E., Hebert, A. A., Muraro, A., Oranje, A. P., Paller, A. S., Paul, C., Puig, L., Ring, J., Siegfried, E., ... Wahn, U. (2015). Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 26(4), 306-315. https://doi.org/10.1111/pai.12331

Luger, T, Boguniewicz, M, Carr, W, Cork, M, Deleuran, M, Eichenfield, L, Eigenmann, P, Fölster-Holst, R, Gelmetti, C, Gollnick, H, Hamelmann, E, Hebert, AA, Muraro, A, Oranje, AP, Paller, AS, Paul, C, Puig, L, Ring, J, Siegfried, E, Spergel, JM, Stingl, G, Taieb, A, Torrelo, A, Werfel, T & Wahn, U 2015, 'Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants', Pediatric Allergy and Immunology, vol. 26, no. 4, pp. 306-315. https://doi.org/10.1111/pai.12331

@article{615b2eac61444614ae50473ad1e99142,

title = "Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants",

abstract = "Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (",

keywords = "Atopic dermatitis, Eczema, Infants, Paediatric, Pimecrolimus, Safety, Tacrolimus, Topical calcineurin inhibitors, Topical corticosteroids",

author = "Thomas Luger and Mark Boguniewicz and Warner Carr and Michael Cork and Mette Deleuran and Lawrence Eichenfield and Philippe Eigenmann and Regina F{\"o}lster-Holst and Carlo Gelmetti and Harald Gollnick and Eckard Hamelmann and Hebert, {Adelaide A.} and Antonella Muraro and Oranje, {Arnold P.} and Paller, {Amy S.} and Carle Paul and Luis Puig and Johannes Ring and Elaine Siegfried and Spergel, {Jonathan M.} and Georg Stingl and Alain Taieb and Antonio Torrelo and Thomas Werfel and Ulrich Wahn",

year = "2015",

month = jun,

day = "1",

doi = "10.1111/pai.12331",

language = "English",

volume = "26",

pages = "306--315",

journal = "Pediatric Allergy and Immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "4",

}

TY - JOUR

T1 - Pimecrolimus in atopic dermatitis

T2 - Consensus on safety and the need to allow use in infants

AU - Luger, Thomas

AU - Boguniewicz, Mark

AU - Carr, Warner

AU - Cork, Michael

AU - Deleuran, Mette

AU - Eichenfield, Lawrence

AU - Eigenmann, Philippe

AU - Fölster-Holst, Regina

AU - Gelmetti, Carlo

AU - Gollnick, Harald

AU - Hamelmann, Eckard

AU - Hebert, Adelaide A.

AU - Muraro, Antonella

AU - Oranje, Arnold P.

AU - Paller, Amy S.

AU - Paul, Carle

AU - Puig, Luis

AU - Ring, Johannes

AU - Siegfried, Elaine

AU - Spergel, Jonathan M.

AU - Stingl, Georg

AU - Taieb, Alain

AU - Torrelo, Antonio

AU - Werfel, Thomas

AU - Wahn, Ulrich

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (

AB - Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. The introduction of the topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, more than 10 yr ago was a major breakthrough for the topical anti-inflammatory treatment of AD. Pimecrolimus 1% is approved for second-line use in children (≥2 yr old) and adults with mild-to-moderate AD. The age restriction was emphasized in a boxed warning added by the FDA in January 2006, which also highlights the lack of long-term safety data and the theoretical risk of skin malignancy and lymphoma. Since then, pimecrolimus has been extensively investigated in short- and long-term studies including over 4000 infants (

KW - Atopic dermatitis

KW - Eczema

KW - Infants

KW - Paediatric

KW - Pimecrolimus

KW - Safety

KW - Tacrolimus

KW - Topical calcineurin inhibitors

KW - Topical corticosteroids

UR - http://www.scopus.com/inward/record.url?scp=84929702549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929702549&partnerID=8YFLogxK

U2 - 10.1111/pai.12331

DO - 10.1111/pai.12331

M3 - Article

AN - SCOPUS:84929702549

SN - 0905-6157

VL - 26

SP - 306

EP - 315

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

IS - 4

ER -

Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this